OBJECTIVES: To investigate whether the inclusion of occult cancer in the control group can influence the association of prostate cancer and the polymorphism of manganese superoxide dismutase (MnSOD). METHODS: Prostate specimens and sera were obtained from 194 deceased men who did not have a history of prostate cancer. Eighteen-core biopsy specimens and whole-mount sections were evaluated histologically. The MnSOD genotype of the specimens was determined by polymerase chain reaction restriction fragment length polymorphism analysis. RESULTS: Tumors were present in 57 of the prostates, and biopsy detected 33 (including 1 false-positive finding). It detected 17 (1 false-positive finding) and missed 14 tumors in the subgroup of 135 specimens with a prostatic-specific antigen <4 ng/mL. The MnSOD AA genotype was associated with prostate cancer found in the step-sectioned specimens vs the control group in whom the absence of occult prostate cancer had been verified. However, no association was found if the control group consisted of subjects with negative biopsy results from the overall group or the subgroup with a prostatic-specific antigen level of <4 ng/mL. CONCLUSIONS: The MnSOD AA genotype was associated with prostate cancer in our study; however, contamination of occult prostate cancer in the control group reduced the power of analysis and might yield seemingly negative results. Epidemiologic studies should strive to include control groups with a verified absence of occult cancer.
OBJECTIVES: To investigate whether the inclusion of occult cancer in the control group can influence the association of prostate cancer and the polymorphism of manganese superoxide dismutase (MnSOD). METHODS: Prostate specimens and sera were obtained from 194 deceased men who did not have a history of prostate cancer. Eighteen-core biopsy specimens and whole-mount sections were evaluated histologically. The MnSOD genotype of the specimens was determined by polymerase chain reaction restriction fragment length polymorphism analysis. RESULTS:Tumors were present in 57 of the prostates, and biopsy detected 33 (including 1 false-positive finding). It detected 17 (1 false-positive finding) and missed 14 tumors in the subgroup of 135 specimens with a prostatic-specific antigen <4 ng/mL. The MnSOD AA genotype was associated with prostate cancer found in the step-sectioned specimens vs the control group in whom the absence of occult prostate cancer had been verified. However, no association was found if the control group consisted of subjects with negative biopsy results from the overall group or the subgroup with a prostatic-specific antigen level of <4 ng/mL. CONCLUSIONS: The MnSOD AA genotype was associated with prostate cancer in our study; however, contamination of occult prostate cancer in the control group reduced the power of analysis and might yield seemingly negative results. Epidemiologic studies should strive to include control groups with a verified absence of occult cancer.
Authors: Richard F Jones; Robert Sunheimer; Henry Friedman; David Miller; Ronald Ginsburg; Mary Jumbelic; Gregory Threatte; Gabriel P Haas Journal: Anticancer Res Date: 2005 Mar-Apr Impact factor: 2.480
Authors: Haojie Li; Philip W Kantoff; Edward Giovannucci; Michael F Leitzmann; J Michael Gaziano; Meir J Stampfer; Jing Ma Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: Ganesh S Palapattu; Siobhan Sutcliffe; Patrick J Bastian; Elizabeth A Platz; Angelo M De Marzo; William B Isaacs; William G Nelson Journal: Carcinogenesis Date: 2004-10-21 Impact factor: 4.944
Authors: S Shimoda-Matsubayashi; H Matsumine; T Kobayashi; Y Nakagawa-Hattori; Y Shimizu; Y Mizuno Journal: Biochem Biophys Res Commun Date: 1996-09-13 Impact factor: 3.575
Authors: Karen Woodson; Joseph A Tangrea; Teresa A Lehman; Ramakrishna Modali; Kristin M Taylor; Kirk Snyder; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Causes Control Date: 2003-08 Impact factor: 2.506
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Chen Mao; Li-Xin Qiu; Ping Zhan; Kai Xue; Hong Ding; Fang-Bing Du; Jin Li; Qing Chen Journal: J Cancer Res Clin Oncol Date: 2009-12-10 Impact factor: 4.553
Authors: N B Delongchamps; G de la Roza; V Chandan; R Jones; G Threatte; M Jumbelic; G P Haas Journal: Prostate Cancer Prostatic Dis Date: 2008-07-15 Impact factor: 5.554
Authors: Taro Iguchi; Ching Y Wang; Nicolas B Delongchamps; Robert Sunheimer; Tatsuya Nakatani; Gustavo de la Roza; Gabriel P Haas Journal: Anticancer Res Date: 2008 Sep-Oct Impact factor: 2.480
Authors: Taro Iguchi; Shozo Sugita; Ching Y Wang; Nancy B Newman; Tatsuya Nakatani; Gabriel P Haas Journal: In Vivo Date: 2009 Jan-Feb Impact factor: 2.155
Authors: Taro Iguchi; Ching Y Wang; Nicolas B Delongchamps; Minoru Kato; Satoshi Tamada; Takeshi Yamasaki; Gustavo de la Roza; Tatsuya Nakatani; Gabriel P Haas Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240